Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Net Income (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Net Income for 6 consecutive years, with -$17.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 426.6% to -$17.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$21.0 million, a 59.78% increase, with the full-year FY2025 number at -$21.0 million, up 59.8% from a year prior.
  • Net Income was -$17.7 million for Q4 2025 at GeneDx Holdings, down from -$7.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $10.8 million in Q2 2025 to a low of -$308.7 million in Q4 2022.
  • A 5-year average of -$61.8 million and a median of -$41.2 million in 2021 define the central range for Net Income.
  • Peak YoY movement for Net Income: tumbled 280529.9% in 2021, then soared 137.05% in 2025.
  • GeneDx Holdings' Net Income stood at -$40.2 million in 2021, then plummeted by 668.23% to -$308.7 million in 2022, then skyrocketed by 91.66% to -$25.8 million in 2023, then skyrocketed by 121.02% to $5.4 million in 2024, then crashed by 426.6% to -$17.7 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Net Income are -$17.7 million (Q4 2025), -$7.6 million (Q3 2025), and $10.8 million (Q2 2025).